Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirilumab + Rituximab in CLL/SLL
NCT02481297Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2015
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lirilumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2015; status: completed.
02
Drugs
lirilumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02481297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481297.